News on Medial

EV charging startup RoadGrid raises Rs 12 Cr in pre-Series A round

EntrackrEntrackr · 2d ago
EV charging startup RoadGrid raises Rs 12 Cr in pre-Series A round
Medial

EV charging infrastructure startup RoadGrid has raised Rs 12 crore ($1.33 million) in a pre-Series A funding round led by Venture Catalysts, with participation from a mix of strategic and angel investors. The round also saw backing from Kamal Puri (Skyline Group), IPV, FAAD Network, LetsVenture, Vrinda Goyal (Pace Group), Haresh Patel (Arthanomics), and Maneesh Shrivastav (Alpha Value). The proceeds will be used to scale manufacturing, expand software integrations, and accelerate the nationwide rollout of charging stations. RoadGrid is building patented universal EV chargers that work across vehicle categories, including two-wheelers, three-wheelers, and four-wheelers. Alongside hardware, the company is developing a cloud-based software platform to manage charging operations and improve the end-user experience. RoadGrid operates across two segments. The first focuses on manufacturing and supplying chargers to EV OEMs, covering off-board and fast DC charging needs. The second involves setting up and operating public and commercial charging stations. The firm has active deployments in locations including Indore, Noida, and IOCL sites, and claims a confirmed pipeline of over 1,000 chargers. It also supplies chargers to EV manufacturers and fleet operators, with deployments supporting companies such as Euler Motors and VinFast’s India network.

Related News

Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr

EntrackrEntrackr · 1y ago
Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr
Medial

Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The board at Immuneel Therapeutic has passed a special resolution to issue 1o equity shares and 8,164 Series A1 CCPS at an issue price of Rs 1,22,330 each to raise Rs 100 crore or $12 million, its regulatory filing accessed from the Registrar of Companies show. The company will use these investments for growth and expansion as decided by the board, the filings further added. As per TheKredible’s estimates, the firm has been valued at around Rs 587 crore or $71 million (post-allotment). Following the fresh proceeds, Taiba Middle East FZ holds a 17% stake in Immuneel Therapeutics. The round appears to be ongoing and it may raise more funds. The company has raised around $40 million to date including its $15 million Series A financing co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022. Founded by Biocon founder Kiran Mazumdar Shaw, oncologist and Pulitzer winner — Siddhartha Mukherjee and Kush Parwar, Immuneel Therapeutics is an Indian clinical-stage startup which is engaged in developing cell and gene therapies for cancer patients. It’s also working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer. The firm claims to offer therapies at one-third of the costs borne for gene therapies in America. While the company is yet to file its annual statements for FY24, six-year-old Immuneel Therapeutics remained at a pre-revenue stage in FY23. Its losses stood at Rs 39 crore in the fiscal year ending March 2023.

Download the medial app to read full posts, comements and news.